移植前BKPyV血清学状态对肾移植后BKPyV感染风险的影响
本回顾性研究纳入329例受者和222例匹配供者,检测移植前BKPyV血清型I和IV的IgG抗体,并监测移植后至少1年BKPyV DNA载量。结果显示供受者血清状态及受者平均抗体滴度与移植后BKPyV病毒血症风险显著相关,提示移植前血清学检测有助于识别高危患者。
要点
- 供者血清型I阳性而受者阴性时,移植后病毒血症概率最高(37.5%)。
- 受者平均滴度<400者病毒血症比例50%,≥400者降至13.5%。
- 低滴度组推断性肾病比例更高(50% vs 23.1%)。
核心结论
- 移植前供受者BKPyV血清状态及受者抗体滴度测定可预测移植后BKPyV病毒血症风险,有助于临床管理。
研究设计与样本
- 回顾性研究,纳入329例肾移植受者和222例匹配供者,检测移植前抗BKPyV血清型I和IV的IgG抗体,并监测移植后至少1年BKPyV DNA载量。
主要发现
- 血清型I病毒血症概率:D-/R+组4.3%,D+/R+组12.1%,D+/R-组37.5%(P < 0.05)。
- 受者平均滴度<400者病毒血症比例50%,≥400者13.5%(P < 0.001)。
- 推断性肾病比例:低滴度组50%,高滴度组23.1%(P < 0.05)。
- 单变量分析中,低滴度对移植后BKPyV病毒血症风险的OR为6.41(95%CI 3.16-13.07;P < 0.0001)。
临床怎么用
- 移植前可检测供受者BKPyV血清状态及受者抗体滴度,识别移植后BKPyV感染高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: BK polyomavirus-associated nephropathy is a troublesome disease caused by BK polyomavirus (BKPyV) infection in immunocompromised renal graft recipients. There are no effective treatments available, making immunosuppression reduction the only management option. Thus, pre-graft predictive BKPyV replication markers are needed for identification of patients at high risk of viraemia. METHODS: We conducted a retrospective study to assess the correlation between pre-transplantation BKPyV serostatus and post-transplantation incidence of BKPyV infection. Sera from 329 recipients and 222 matched donors were tested for anti-BKPyV antibodies against BKPyV serotypes I and IV by using a virus-like particle-based immunoglobulin G enzyme-linked immunosorbent assay, and BKPyV DNA load was monitored for at least 1 year post-transplantation. RESULTS: Eighty recipients were viruric and 59 recipients were viraemic post-transplantation. In the post-transplantation period, the probability of developing viraemia for serotype I increased from 4.3% for the D-/R+ group to 12.1% for the D+/R+ group, climbing to 37.5% for the D+/R- group (P < 0.05). When calculating recipient mean titres for serotypes I and IV, we observed a clear difference in the proportions of viraemia, decreasing from 50% for mean titres <400 to 13.5% for titres ≥400 (P < 0.001), as well as a higher proportion of presumptive nephropathy (50% versus 23.1%, respectively; P < 0.05). In univariate analysis, this parameter had an odds ratio of 6.41 for the risk of developing post-transplantation BKPyV viraemia (95% confidence interval 3.16-13.07; P < 0.0001). CONCLUSIONS: Determination of both donor and recipient BKPyV seropositivity before transplantation and antibody titre measurements may serve as a predictive tool to manage clinical BKPyV infection by identification of patients at high risk.
引用
- François C, Tinez C, Brochot E, et al. Impact of pre-graft serology on risk of BKPyV infection post-renal transplantation. Nephrol Dial Transplant. 2022. PMID: 34586413. doi:10.1093/ndt/gfab279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。